GlassScriptPhysician profile
James Gonzales
NPI 1518948728
$669.74
in general payments reported to CMS, 2019-2025
15 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.09 · 2021: $44.77 · 2022: $85.01 · 2023: $256 · 2024: $130 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $142.35 | 2022-2023 | Relieva Spinplus, Acclarent Navwire |
| Merz North America, INC. | $62.97 | 2024 | |
| Medtronic, INC. | $58.12 | 2023-2024 | Propel |
| Genzyme Corporation | $57.68 | 2021-2025 | |
| Neurent Medical Limited | $57.58 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Optinose US, INC. | $49.59 | 2019-2023 | |
| Hikma Pharmaceuticals USA | $47.14 | 2023-2024 | Ryaltris |
| Glaxosmithkline, LLC. | $33.72 | 2022-2023 | Nucala |
| Integra Lifesciences Corporation | $30.85 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Intersect Ent, INC. | $28.45 | 2022 | |
| Merck Sharp & Dohme LLC | $24.83 | 2023 | |
| Olympus America INC. | $24.78 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $22.47 | 2021 | |
| Abiomed | $15.14 | 2024 | Impella |
| Boston Scientific Corporation | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.